The United Laboratories International Holdings Limited

Equities

3933

KYG8813K1085

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
8.96 HKD -3.03% Intraday chart for The United Laboratories International Holdings Limited -6.08% +27.82%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
The United Laboratories International Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
The United Laboratories International's 2023 Profit Rises on Higher Revenue MT
The United Laboratories International Forecasts Profit Surge in 2023 MT
The United Laboratories International Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended 31 December 2023 CI
United Laboratories Postpones EGM Due to Bad Weather MT
United Laboratories Subsidiary Gets US FDA Nod for Injectable for Diabetes; Shares Rise 8% MT
The United Laboratories International Holdings Limited Announces FDA Approval of IND for UBT251 Injection CI
The United Laboratories International Holdings Limited Announces Interim Dividend for Six Months Ended 30 June 2023, Payable on 11 October 2023 CI
United Laboratories Controlling Shareholder to Sell 64 Million Shares MT
United Laboratories International Unit Gets Regulatory Nod to Conduct Trial on TUL01101 Tablets MT
Chinese Regulator Allows Clinical Trial of United Laboratories' Fatty-Liver Drug MT
The United Laboratories International Holdings Limited Announces Application for the Clinical Trial of Class 1 Innovative New Drug UBT251 Injection CI
United Laboratories International Says Two Products Pass Consistency Evaluation MT
China Greenlights United Laboratories' Clinical Trial for Obesity Injection; Shares Rise 4% MT
The United Laboratories International Holdings Limited Announces Approval for Clinical Trial of Ubt251 Injection on Indication of Overweight or Obesity CI
The United Laboratories International Holdings Limited Announces Ordinary Interim (Semi-Annual) Dividend for Six Months Ended 30 June 2023 CI
United Laboratories' H1 Profit Doubles; Shares Fall 4% MT
The United Laboratories International Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
The United Laboratories International Holdings Limited Announces Approval of the New Drug, TUL12101 CI
Chinese Drug Regulator Accepts United Laboratories International Unit's Application for Marketing of Diabetes Drug; Shares Up 3% MT
United Laboratories Expects H1 Profit to Nearly Double; Shares Surge 10% MT
The United Laboratories International Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2023 CI
United Laboratories International Holdings Unit's Injection for Pneumonia Passes China's Consistency Evaluation MT
The United Laboratories International Holdings Limited Approves Final Dividend for the Year Ended 31 December 2022, Payable on 26 July 2023 CI
The United Laboratories International Holdings Limited Approves Final Dividend for the Year Ended 31 December 2022, Payable on 26 July 2023 CI
Chart The United Laboratories International Holdings Limited
More charts
The United Laboratories International Holdings Limited is an investment holding company principally engaged in the sales of intermediate products, bulk medicine and finished products. The Company operates its business through three segments. The Intermediate Products segment is engaged in the sale of intermediate products. The Bulk Medicine segment is engaged in the sale of bulk medicine. The Finished Products segment is engaged in the sale of antibiotics finished products, non-antibiotics finished products and capsule casings. Through its subsidiaries, the Company is also engaged in the production and sale of organic fertilizer.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
9.24 HKD
Average target price
11.39 HKD
Spread / Average Target
+23.27%
Consensus